KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cost of Revenue (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Cost of Revenue for 6 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 56.25% year-over-year to $9.5 million, compared with a TTM value of $19.1 million through Dec 2025, up 55.47%, and an annual FY2025 reading of $19.1 million, up 55.47% over the prior year.
  • Cost of Revenue was $9.5 million for Q4 2025 at Biocryst Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $9.5 million in Q4 2025 and bottomed at $1.3 million in Q1 2024.
  • Average Cost of Revenue over 3 years is $3.9 million, with a median of $3.2 million recorded in 2024.
  • Peak annual rise in Cost of Revenue hit 261.11% in 2025, while the deepest fall reached 31.89% in 2025.
  • Year by year, Cost of Revenue stood at $4.0 million in 2023, then surged by 53.35% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025.
  • Business Quant data shows Cost of Revenue for BCRX at $9.5 million in Q4 2025, $2.2 million in Q3 2025, and $2.8 million in Q2 2025.